Compare Moderna, Inc. (MRNA) vs Zillow Group Inc Class C (Z) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Zillow Group (Z) trades at $33.10, down 1.93% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is solid, rising to $2.58B in 2025, but profitability remains thin with a net margin of 1.96%. The stock faces headwinds from a securities class action lawsuit and a challenging real estate market, though analyst consensus points to significant upside with a $52 price target.

The outlook is cautious due to legal risks and weak near-term profitability, but long-term monetization potential and analyst optimism suggest opportunity if execution improves. Key risks include litigation outcomes and market volatility, while institutional sentiment leans neutral with a 50% hold rating.